Are maintenance and continuous therapies indicated for every patient with multiple myeloma?

Pellegrino Musto, Vittorio Montefusco

Research output: Contribution to journalArticlepeer-review

Abstract

Maintenance therapy after autologous stem cell transplantation, as well as continuous regimens for older, transplant ineligible patients, are emerging as an effective strategy to control the minimal residual disease that persists after response to initial treatments and is the main cause of relapse in patients affected by multiple myeloma (MM). However, though such approaches have consistently demonstrated in clinical trials to be able to delay disease recurrence, thus improving progression-free survival and, at least in some studies, overall survival, the use of these long term therapies (LTTs) in the daily clinical practice is not uniformly applied and some questions remains unanswered. This article aims to provide a synthetic discussion of the most consistent data on novel agent-based LTTs in newly diagnosed MM, to recognize the best candidate for these treatments and to describe a landscape of their possible future application.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalExpert Review of Hematology
DOIs
Publication statusAccepted/In press - Jun 16 2016

Keywords

  • bortezomib
  • carfilzomib
  • continuous therapy
  • daratumumab
  • elotuzumab
  • ixazomib
  • lenalidomide
  • maintenance therapy
  • minimal residual disease
  • Multiple myeloma
  • thalidomide

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Are maintenance and continuous therapies indicated for every patient with multiple myeloma?'. Together they form a unique fingerprint.

Cite this